Your browser is no longer supported. Please, upgrade your browser.
Settings
CPRX Catalyst Pharmaceuticals, Inc. daily Stock Chart
CPRX [NASD]
Catalyst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.21 Insider Own5.30% Shs Outstand101.04M Perf Week-1.86%
Market Cap320.30M Forward P/E- EPS next Y-0.08 Insider Trans1.32% Shs Float95.64M Perf Month-11.20%
Income-19.10M PEG- EPS next Q-0.08 Inst Own53.70% Short Float2.03% Perf Quarter24.80%
Sales- P/S- EPS this Y1.60% Inst Trans-0.42% Short Ratio2.56 Perf Half Y-16.80%
Book/sh0.74 P/B4.28 EPS next Y77.10% ROA-32.60% Target Price7.00 Perf Year12.01%
Cash/sh0.77 P/C4.11 EPS next 5Y- ROE-34.40% 52W Range2.09 - 4.51 Perf YTD-18.93%
Dividend- P/FCF- EPS past 5Y-9.60% ROI- 52W High-29.71% Beta1.24
Dividend %- Quick Ratio28.90 Sales past 5Y- Gross Margin- 52W Low51.67% ATR0.15
Employees21 Current Ratio28.90 Sales Q/Q- Oper. Margin- RSI (14)44.16 Volatility5.38% 4.78%
OptionableYes Debt/Eq0.00 EPS Q/Q7.20% Profit Margin- Rel Volume0.58 Prev Close3.23
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume756.46K Price3.17
Recom1.80 SMA20-2.72% SMA50-3.65% SMA200-1.32% Volume439,218 Change-1.86%
Oct-05-16Upgrade Piper Jaffray Neutral → Overweight
Apr-26-16Downgrade Piper Jaffray Overweight → Neutral $6 → $1
Sep-30-14Reiterated ROTH Capital Buy $5 → $6
Sep-16-14Reiterated ROTH Capital Buy $3.50 → $5
Sep-15-14Reiterated H.C. Wainwright Buy $5 → $13
Oct-21-13Reiterated Aegis Capital Buy $4 → $5.50
Sep-24-13Initiated Maxim Group Buy $4
Sep-06-13Reiterated Aegis Capital Buy $3.50 → $4
Apr-18-13Initiated Aegis Capital Buy $2.50
Aug-27-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $3.70
Oct-01-09Upgrade Merriman Sell → Neutral
May-29-09Downgrade Merriman Curhan Ford Buy → Sell
May-29-09Downgrade Hapoalim Neutral → Underperform
Dec-15-08Initiated Merriman Curhan Ford Buy
Nov-28-07Initiated Rodman & Renshaw Mkt Outperform $9
Jan-31-07Initiated Stifel Nicolaus Buy $9
Jan-05-07Initiated First Albany Buy $10
Jun-28-18 07:50AM  Free Research Reports on Catalent and Three More Generic Drugs Stocks ACCESSWIRE
Jun-13-18 08:03AM  Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer GlobeNewswire
Jun-12-18 08:00AM  Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors GlobeNewswire
May-31-18 08:03AM  Catalyst Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-29-18 08:03AM  Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse® (Amifampridine Phosphate) for Lambert-Eaton Myasthenic Syndrome GlobeNewswire +8.59%
May-18-18 07:40AM  Wired News FDA Granted Approval to Eagle Pharmas Bendamustine Hydrochloride RTD Solution in a 500ml Admixture ACCESSWIRE
May-09-18 07:56PM  Catalyst: 1Q Earnings Snapshot Associated Press
04:13PM  Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-02-18 08:03AM  Catalyst Pharmaceuticals to Hold First Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, May 10th, 2018 GlobeNewswire
Apr-20-18 08:10AM  Report: Developing Opportunities within Clean Energy Fuels, Catalyst Pharmaceuticals, Qorvo, Brunswick, DCT Industrial Trust, and Radius Health Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-19-18 08:03AM  Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis GlobeNewswire
Mar-29-18 02:20PM  Catalyst Pharmaceuticals files new drug application with FDA American City Business Journals
08:19AM  Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic Syndrome GlobeNewswire
Mar-14-18 04:20PM  Catalyst reports 4Q loss Associated Press
04:13PM  Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update GlobeNewswire
02:58PM  Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now Insider Monkey
09:50AM  When Will Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Breakeven? Simply Wall St.
Mar-12-18 08:03AM  Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast GlobeNewswire
Mar-08-18 08:04AM  Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results Conference Call and Webcast on Thursday, March 15th, 2018 GlobeNewswire
Mar-05-18 09:35AM  What's in Store for Catalyst (CPRX) This Earnings Season? Zacks
Feb-28-18 08:03AM  Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018 GlobeNewswire
Feb-15-18 07:35AM  Detailed Research: Economic Perspectives on Carbo Ceramics, Consolidated Communications, Catalyst Pharmaceuticals, Office Depot, ImmunoGen, and Cedar Realty Trust What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-12-18 08:03AM  Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse® GlobeNewswire
Feb-07-18 08:03AM  Catalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire
Dec-02-17 10:33AM  3 Drug Stocks That Soared This Week: Are They Buys? Motley Fool
Nov-30-17 02:07PM  Catalyst Pharmaceuticals, Inc. Announces Closing of Previously Announced Public Offering GlobeNewswire +8.31%
08:20AM  Analysis: Positioning to Benefit within Office Depot, ImmunoGen, Cedar Realty Trust, Carbo Ceramics, Consolidated Communications, and Catalyst Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-28-17 09:17AM  Catalyst Pharmaceuticals, Inc. Prices Previously Announced Public Offering of Common Stock Marketwired +10.25%
Nov-27-17 04:03PM  Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
06:30AM  Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome GlobeNewswire
Nov-21-17 08:03AM  Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy (SMA) GlobeNewswire +6.86%
Nov-08-17 06:33PM  Catalyst reports 3Q loss Associated Press
04:41PM  Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
09:59AM  Have Investors Already Priced In Catalyst Pharmaceuticals Incs (CPRX) Growth? Simply Wall St.
Nov-06-17 10:33AM  What's in Store for Catalyst (CPRX) This Earnings Season? Zacks +5.70%
Nov-01-17 08:03AM  Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9th, 2017 GlobeNewswire
Oct-31-17 08:03AM  Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome GlobeNewswire +7.92%
Oct-16-17 08:03AM  Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum GlobeNewswire
Aug-30-17 08:03AM  Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities GlobeNewswire
Aug-10-17 06:40AM  Investor Network: Catalyst Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-09-17 10:00PM  Catalyst reports 2Q loss Associated Press
04:30PM  Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Aug-01-17 08:03AM  Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10th, 2017 GlobeNewswire -6.12%
Jul-12-17 08:10AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Catalyst Pharmaceuticals Inc. Accesswire
Jun-26-17 08:03AM  Catalyst Pharmaceuticals Joins Russell 3000 Index GlobeNewswire
Jun-07-17 11:05AM  Three Junior Biotechs Ready to Run Investopedia
Jun-01-17 08:03AM  Catalyst Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference GlobeNewswire +5.19%
May-17-17 08:03AM  Catalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium GlobeNewswire
May-12-17 11:26AM  Catalyst Pharmaceuticals Receives 2017 Beacon Council Award for Contributions in Life Sciences & Healthcare GlobeNewswire +5.98%
May-11-17 07:30AM  Investor Network: Catalyst Pharmaceuticals, Inc. to Host Earnings Call Accesswire
May-10-17 05:34PM  Catalyst reports 1Q loss Associated Press
04:35PM  Catalyst Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
11:25AM  Catalyst Pharmaceuticals Announces Poster Presentation of MuSK-MG clinical data at the 13th International Conference on Myasthenia Gravis and Related Disorders GlobeNewswire
May-02-17 06:40PM  What's in Store for Catalyst (CPRX) Stock in Q1 Earnings? Zacks
08:03AM  Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 11th, 2017 GlobeNewswire
Mar-28-17 09:30AM  Catalyst Pharmaceuticals and ZIOPHARM Oncology Bounce Up On FDA Phase News Accesswire -5.47%
08:15AM  Catalyst Pharmaceuticals (CPRX) Jumps: Stock Gains 18.2%
Mar-24-17 01:04PM  CATALYST PHARMACEUTICALS, INC. Financials
Mar-23-17 09:47AM  Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse
Mar-21-17 09:30AM  Financials of Aurinia Pharmaceuticals and Catalyst Pharmaceuticals are Getting Stability Accesswire
Mar-16-17 12:03PM  Catalyst Pharmaceuticals Inc (CPRX): Heres Whats Next Insider Monkey
12:03PM  Catalyst Pharmaceuticals Inc (CPRX): Heres Whats Next at Insider Monkey
Mar-15-17 04:51PM  Catalyst reports 4Q loss Associated Press +32.48%
04:44PM  CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:32PM  Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update GlobeNewswire
03:17PM  Catalyst Pharma Neuromuscular Drug Succeeds In Study Investopedia
03:17PM  Catalyst Pharma Neuromuscular Drug Succeeds In Study at Investopedia
01:19PM  Heres Why Traders Are Piling Into These Five Stocks Insider Monkey
01:19PM  Heres Why Traders Are Piling Into These Five Stocks at Insider Monkey
12:10PM  Wednesdays Biggest Biopharma Movers
08:58AM  Catalyst Pharma shares jump 22% premarket on news of positive trial results for rare disease MarketWatch
08:58AM  Catalyst Pharma shares jump 22% premarket on news of positive trial results for rare disease at MarketWatch
08:57AM  Catalyst Pharma's neuromuscular drug succeeds in study Reuters
08:19AM  Catalyst Pharma's neuromuscular drug succeeds in study Reuters
08:03AM  Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse® in treating MuSK Antibody Positive Myasthenia Gravis GlobeNewswire
07:07AM  Q4 2016 Catalyst Pharmaceuticals Inc Earnings Release - After Market Close
Mar-10-17 08:03AM  Catalyst Pharmaceuticals to Present at the 29th Annual ROTH Conference GlobeNewswire
Mar-09-17 08:03AM  Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast on Thursday, March 16th, 2017 GlobeNewswire
Mar-07-17 09:32AM  Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
Feb-27-17 08:03AM  Catalyst Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases GlobeNewswire
Feb-09-17 04:05PM  Catalyst Pharmaceuticals Announces Participation at SunTrust Robinson Humphreys 2017 Orphan Drug Day GlobeNewswire
Dec-16-16 08:16AM  Harvard Bioscience, Inc. (HBIO): Are Hedge Funds Right About This Stock? at Insider Monkey
Dec-15-16 08:44AM  CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:03AM  Catalyst Pharmaceuticals Announces First Patient Enrolled in Second Phase 3 Trial of Firdapse in Lambert-Eaton myasthenic syndrome (LEMS) GlobeNewswire
Dec-08-16 08:39AM  CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:03AM  Catalyst Pharmaceuticals Provides Update on its Clinical Trial for Patients with Congenital Myasthenic Syndromes GlobeNewswire
Dec-01-16 08:46AM  Catalyst Pharmaceuticals, Inc. :CPRX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-21-16 08:03AM  Catalyst Pharmaceuticals to Participate in the 28th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-14-16 08:35AM  Alexion (ALXN) Offers Long-Term Phase III Data on Kanuma
Nov-09-16 05:59PM  Catalyst reports 3Q loss
05:02PM  CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:21PM  Catalyst Pharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
04:15PM  CATALYST PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
07:07AM  Q3 2016 Catalyst Pharmaceuticals Inc Earnings Release - After Market Close
Nov-07-16 08:25AM  Catalyst Pharma (CPRX) Q3 Earnings: Will Stock Surprise?
Nov-03-16 08:37AM  Catalyst Reaches Agreement with FDA (CPRX) at Investopedia
Nov-01-16 01:28PM  Catalyst Pharmaceuticals Inc (CPRX) Isnt Out Of The Woods With Firdapse Just Yet at Insider Monkey
08:03AM  Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 10th, 2016 GlobeNewswire
Oct-31-16 11:15AM  Research Reports Coverage on Generic Drugs Stocks -- Evoke Pharma, Catalyst Pharma, Neurocrine Biosciences, and Galectin Therapeutics PR Newswire +6.92%
08:13AM  CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DENKHAUS DONALD ADirectorJun 08Buy3.4120,00068,200140,000Jun 11 08:48 AM
O'Keeffe Charles BDirectorJun 07Buy3.314,00013,222522,376Jun 07 03:35 PM
O'Keeffe Charles BDirectorJun 07Buy3.351,0003,352523,376Jun 08 04:26 PM
O'Keeffe Charles BDirectorJun 01Buy3.745,00018,680518,376Jun 01 04:21 PM
DENKHAUS DONALD ADirectorMay 30Buy3.7520,00075,000120,000May 31 11:57 AM
MCENANY PATRICK JPresident and CEOApr 03Buy2.2920,00045,8004,717,693Apr 03 04:13 PM
O'Keeffe Charles BDirectorNov 16Option Exercise0.4750,00023,500513,376Nov 17 05:09 PM
COELHO PHILIP HDirectorNov 09Option Exercise0.4750,00023,500223,287Nov 13 04:22 PM
Tierney David SDirectorNov 09Option Exercise0.4750,00023,500313,401Nov 13 04:20 PM
MCENANY PATRICK JPresident and CEONov 06Option Exercise0.47200,00094,0004,671,026Nov 07 05:13 PM
GRANDE ALICIAChief Financial OfficerNov 06Option Exercise0.47200,00094,000396,346Nov 07 05:12 PM
Miller SteveChief Operating OfficerNov 06Option Exercise0.47200,00094,000657,687Nov 07 05:12 PM
MCENANY PATRICK JPresident and CEOSep 05Buy2.5820,00051,5604,471,026Sep 05 11:00 AM